Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

3 Months Ended

Jan. 31, 2013

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2013
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,320			—			—			—		$	13,320
Product revenues		—		$	7,876			—			—			7,876
Royalty and license fee income		—			1,014			—			—			1,014
		13,320			8,890			—			—			22,210
Operating expenses:
Cost of clinical laboratory services		9,425			—			—			—			9,425
Cost of product revenues		—			4,143			—			—			4,143
Research and development		86			570		$	312			—			968
Selling, general and administrative		4,911			4,081			—		$	1,900			10,892
Provision for uncollectible accounts receivable		1,213			122			—			—			1,335
Legal		51			31			—			1,359			1,441
Total operating expenses		15,686			8,947			312			3,259			28,204

Operating income (loss)		(2,366	)		(57	)		(312	)		(3,259	)		(5,994	)

Other income (expense)
Interest		(13	)		5			—			1			(7	)
Other		17			17			—			9			43
Foreign currency gain		—			104			—			—			104
Income (loss) before income taxes	$	(2,362	)	$	69		$	(312	)	$	(3,249	)	$	(5,854	)

Depreciation and amortization included above	$	355		$	799		$	7		$	25		$	1,186

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			1			—			—			1
Selling, general and administrative		11		$	6			—		$	140			157
Total	$	13		$	7			—		$	140		$	160

Capital expenditures	$	241		$	87		$	—		$	—		$	328

Three months ended January 31, 2012
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,123			—			—			—		$	14,123
Product revenues		—		$	9,542			—			—			9,542
Royalty and license fee income		—			1,308			—			—			1,308
		14,123			10,850			—			—			24,973
Operating expenses:
Cost of clinical laboratory services		8,709			—			—			—			8,709
Cost of product revenues		—			4,685			—			—			4,685
Research and development		71			1,136		$	496			—			1,703
Selling, general and administrative		5,190			4,227			—		$	2,070			11,487
Provision for uncollectible accounts receivable		1,146			23			—			—			1,169
Legal		69			118			—			836			1,023
Total operating expenses		15,185			10,189			496			2,906			28,776

Operating income (loss)		(1,062	)		661			(496	)		(2,906	)		(3,803	)

Other income (expense)
Interest		(1	)		15			—			—			14
Other		17			45			—			3			65
Foreign currency (loss)		—			(352	)		—			—			(352	)
Income (loss) before income taxes	$	(1,046	)	$	369		$	(496	)	$	(2,903	)	$	(4,076	)

Depreciation and amortization included above	$	269		$	734		$	11		$	31		$	1,045

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	1			—			—			1
Selling, general and administrative		11			20			—		$	182			213
Total	$	14		$	21			—		$	182		$	217

Capital expenditures	$	241		$	62		$	—		$	—		$	303

Six months ended January 31, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,497			—		—			—		$	28,497
Product revenues		—		$	16,309		—			—			16,309
Royalty and license fee income		—			3,033		—			—			3,033
		28,497			19,342		—			—			47,839
Operating expenses:
Cost of clinical laboratory services		19,135			—		—			—			19,135
Cost of product revenues		—			8,327		—			—			8,327
Research and development		175			1,175	$	629			—			1,979
Selling, general and administrative		9,873			8,353		—		$	4,082			22,308
Provision for uncollectible accounts receivable		2,769			160		—			—			2,929
Legal		158			36		—			2,948			3,142
Total operating expenses		32,110			18,051		629			7,030			57,820

Operating income (loss)		(3,613	)		1,291		(629	)		(7,030	)		(9,981	)

Other income (expense)
Interest		(22	)		4		—			3			(15	)
Other		24			20		—			12			56
Foreign currency gain		—			333		—			—			333
Income (loss) before income taxes	$	(3,611	)	$	1,648	$	(629	)	$	(7,015	)	$	(9,607	)

Depreciation and amortization included above	$	663		$	1,604	$	14		$	55		$	2,336

Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—		—			—		$	4
Research and development		—		$	1		—			—			1
Selling, general and administrative		22			6		—		$	268			296
Total	$	26		$	7		—		$	268		$	301

Capital expenditures	$	420		$	170	$	—		$	—		$	590

Six months ended January 31, 2012
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,310			—			—			—		$	28,310
Product revenues		—		$	19,245			—			—			19,245
Royalty and license fee income		—			3,170			—			—			3,170
		28,310			22,415			—			—			50,725
Operating expenses:
Cost of clinical laboratory services		17,523			—			—			—			17,523
Cost of product revenues		—			9,822			—			—			9,822
Research and development		115			2,184		$	1,029			—			3,328
Selling, general and administrative		10,020			9,455			—		$	4,397			23,872
Provision for uncollectible accounts receivable		2,419			36			—			—			2,455
Legal		112			502			—			1,278			1,892
Total operating expenses		30,189			21,999			1,029			5,675			58,892

Operating income (loss)		(1,879	)		416			(1,029	)		(5,675	)		(8,167	)

Other income (expense)
Interest		(2	)		14			—			—			12
Other		22			44			—			10			76
Foreign currency (loss)		—			(323	)		—			—			(323	)
Income (loss) before income taxes	$	(1,859	)	$	151		$	(1,029	)	$	(5,665	)	$	(8,402	)

Depreciation and amortization included above	$	535		$	1,640		$	22		$	62		$	2,259

Share-based compensation included in above:
Cost of clinical laboratory services	$	5			—			—			—		$	5
Research and development		—		$	4			—			—			4
Selling, general and administrative		27			40			—		$	354			421
Total	$	32		$	44			—		$	354		$	430

Capital expenditures	$	431		$	113		$	—		$	—		$	544

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details